By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genelux Corporation 

3030 Bunker Hill Street, Suite 310

San Diego  California  92109  U.S.A.
Phone: 858-483-0024 Fax: 858-483-0026


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
Genelux Corporation Appoints George Vandeman And Thomas Zindrick To Board Of Directors 5/28/2014 11:20:33 AM
Update: Genelux Corporation Announces Former Amgen (AMGN) And Abbott Laboratories (ABT) Executives To Succeed Founder Aladar A. Szalay, Ph.D., As CEO, Chairman Of The Board 5/16/2014 7:39:56 AM
Genelux Corporation Announces Former Amgen (AMGN) And Abbott Laboratories (ABT) Executives To Succeed Founder Aladar A. Szalay, Ph.D., As CEO, Chairman Of The Board 5/12/2014 10:19:46 AM
Genelux Corporation CEO, Dr. Aladar A. Szalay, To Give A Keynote Lecture At The 8th International Conference On Oncolytic Virus Therapeutics 4/9/2014 9:48:21 AM
Genelux Corporation Appoints John D. Prunty Chief Financial Officer 2/11/2014 9:30:13 AM
Genelux Corporation Release: Virus Engineered to Express Melanin Offers New Possibilities to Diagnose and Treat Solid Tumor Cancers 2/13/2013 10:41:19 AM
First Patient Treated in Genelux Corporation Phase I Trial With GL-ONC1 at Memorial Sloan-Kettering Cancer Center 2/6/2013 6:48:04 AM
Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers 11/1/2012 11:13:24 AM
Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients 6/28/2012 9:21:28 AM
Genelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of GL-ONC1 6/14/2012 9:09:30 AM
12
//-->